News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

NAVEX 2024 Global Incident Management Benchmark Study Reveals Significant Third-Party Reporting to Companies

NAVEX Global

NAVEX, the global leader in integrated risk and compliance management software, has released its 2024 Whistleblowing & Incident Management Benchmark Report. The annual benchmark report offers valuable insights into workplace culture, analyzing trends from 1.86 million global reports spanning thousands of organizations that together employ more than 50 million employees. Amid a record number of tips to the SEC and a burgeoning DOJ whistleblowing program, NAVEX’s comprehensive analysis sheds a critical light on the state of workplace environments worldwide, guiding organizations toward program improvement. "NAVEX remains the gold standard in risk and compliance data analytics, continually innovating our benchmarks to enhance corporate compliance programs and offer business leaders insights into the trending risk areas for their organizations," says NAVEX Chief Risk and Compliance Officer Carrie Penman. "This year's report introduces crucial third-party reporting insights, highlighting an organization’s need to adopt internal and external reporting avenues to bolster integrity, foster accountability and equip the organization to tackle emerging challenges effectively.” This year’s analysis of the data revealed several key themes and notable findings, including: Report volume and case substantiation reach milestones. Internal reporting programs saw a record level of use as measured by NAVEX’s Reports per 100 Employees metric. In addition, the Substantiation Rate metric reached an all-time high, meaning more reports were received and more were found to be true. Report volume, and the substantiation rates of the reports received, are two of the most highly watched metrics in the annual NAVEX publication. To see both reach the highest levels ever is good news. For those with trusted and effective internal reporting programs, this added up to greater visibility into the trends of risk, ethics and culture playing out in their organizations’ operations – real-time intelligence to inform business decision-making. In 2023, organizations received a median 1.57 Reports per 100 Employees across their internal reporting systems, exceeding the previous record of 1.47 set in 2022. More organizations (23%) received five or more Reports per 100 Employees, making this population the largest in the NAVEX data set. And while year-over-year values fluctuated, every size of organization – from the smallest companies to enterprises with over 100,000 employees – has seen report volumes rise comparing 2021 and 2023. At 45%, the overall median share of substantiated or founded reports in 2023 reached an 11-year high. Third parties more likely to report business integrity and financial misconduct issues. In a first for this report, NAVEX analyzed its database by both employees and third-party reporters. Its analysis shows these two groups are distinct across several metrics, highlighting the insight organizations see by promoting their reporting programs internally and externally. Third parties as a group delivered a far greater median share of reports related to Business Integrity matters than employees in 2023 (50% versus 17%). Encompassing topics like conflicts of interest, vendor issues, fraud, global trade and human rights, this category of issues can manifest in various elements of a supply chain. Third-party reporters also showed twice the median share of Accounting, Auditing & Financial Reporting reports as employees in 2023 (10% versus 4.5%). Story emerging on accounting-related reporting – internally and externally. Accounting-related reports -- while lower in overall percentage of reports received internally by organizations at a median of 4.3.% in 2023 -- often receive an outsized share of attention due to potential for regulatory action and the well-publicized bounty program offered by the SEC and its Office of the Whistleblower. The SEC's program is witnessing unprecedented growth in tips and generously rewarding valuable information. Now, the U.S. Department of Justice is launching a similar initiative. Specifically, reports related to Accounting, Auditing, and Financial reporting: Showed the longest time between when an incident was observed and when it was reported to the organization By a large margin, were least likely to be reported anonymously Comprised an outsized share of cases for organizations that receive very few Reports per 100 Employees – meaning while these organizations received well below the benchmark number of reports, they had a much more significant percentage of accounting-related reports Experienced the longest time to investigate and close the case Had among the highest median Substantiation Rates, at 50% Were most likely to cause an employment separation event as a result of a substantiated case Accounted for twice as many of the reports submitted by third parties than those submitted by employees Small increase in report volume shows big payoff in healthy report mix. A diverse array of topics, inquiries, and allegations in internal reporting indicates a robust program. NAVEX’s findings reveal that even minor efforts to promote internal reporting significantly improve the mix of report types received. For instance, in organizations with the lowest report volume, only 8.7% of reports pertain to HR, Diversity, and Workplace Respect. However, in the next tier, this proportion jumps to 36.3%. This trend persists across different report volumes, emphasizing the importance of fostering a reporting culture. A varied mix of report types signifies trust in internal reporting to address a broad spectrum of issues. Even a slight increase from minimal reporting yields a more comprehensive and insightful flow of reports. "With NAVEX's integrated data platform, companies gain unparalleled risk signal data that empowers them to foster healthier workplace cultures, helping them achieve outcomes that matter most,” explains NAVEX Chief Product Officer A.G. Lambert. "Data isn't just numbers; it's the compass guiding organizations toward success and ensuring they stay ahead in the ever-evolving landscape of risk and compliance." Additional notable findings include: Workplace behaviors and discord were clearly visible in the data as more organizations return to office environments. As is always the case in these reports, workplace behaviors and other human resources related matters are by far the highest percentage of reports received by organizations. Workplace Civility matters continued to increase in prominence in 2023, representing a median of 18% of reports and the highest median reporting rate in 2023. This was followed by Discrimination, at a median 12%, Harassment, at a median 7.1%, then Retaliation at a median of 2.0%. The HR, Diversity and Workplace Respect category overall has seen a multi-year increase in its median share of all reports (from 50% in 2021 to 55% in 2023). These figures underscore the growing importance of fostering a respectful and inclusive work environment. Highlighting the seriousness with which organizations are taking reports received, more substantiated reports (18%) resulted in separation from employment in 2023, up significantly from 14% in 2022 and 12% in 2021. The share of reports resulting in no action – effectively the opposite end of the outcome spectrum – fell from 17% in 2022 to 14% in 2023. Nearly nine out of 10 reports of Imminent Threat to a Person, Animals or Property were substantiated in 2023 highlighting the importance that reporters possess the training, knowledge, tools and trust that promote rapid reporting of dangerous issues. This need is made even greater by a new California workplace violence prevention law expected to take effect this year that includes requirements for reporting, incident management and training around this issue. For more insights on the 2024 Whistleblowing & Incident Management Benchmark Report, join Jane Norberg, Arnold & Porter partner and former chief of the SEC Office of the Whistleblower, Keith Thomas, FedEx corporate integrity & compliance lead counsel, Carrie Penman, NAVEX chief risk & compliance officer, and Anders Olsen, NAVEX senior data scientist, for an informative webinar where they will discuss the results of this year’s analysis in detail. Watch the webinar here. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global scott.levesque@navex.com Company Website https://navex.com

March 26, 2024 06:00 AM Eastern Daylight Time

Article thumbnail News Release

An Inherited Condition Could be the Cause of Your Early Heart Disease or Stroke, But Your Doctor is Probably Not Testing for It

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/Y_mu9ZpIO88 Heart disease is still the single biggest threat to American health today. Family Heart Foundation research shows that less than 5% of Americans are being screened for the most common, life-threatening genetic condition that causes early strokes and heart attacks – elevated Lipoprotein(a) or Lp(a) for short. Elevated lipoprotein(a) is the most common genetic cause of early heart disease and stroke. One in 5 people worldwide have inherited high Lp(a), and most don’t know it. You inherit your Lp(a) level from your parents. Because elevated Lp(a) isn’t screened for, the first sign of this condition may be a stroke or a heart attack. Elevated levels of Lp(a) increases the risk of blood clotting and plaque buildup inside the blood vessels, which can block the flow of blood and oxygen to your heart and brain. Compared to the general population, people with elevated Lp(a) have 2-3 times the risk for a heart attack and stroke at a young age. The higher your Lp(a), the higher your risk. Lp(a) is not measured in the standard cholesterol panel. It’s important to understand if you have elevated Lp(a). Multiple therapies are in development but in the meantime, there are things you can do to manage your other cardiovascular risk factors, such as keeping your LDL cholesterol levels very low. The Family Heart Foundation can help you find a healthcare provider near you and connect you to others living with elevated Lp(a). The Family Heart Foundation is the only patient-centered, research and advocacy organization focused on addressing the lack of screening and care for people born and living with this common life-threatening condition. On March 20 th a nationwide media tour was conducted featuring Dr. Amit Khera, Professor and Director of Preventive Cardiology UT Southwestern Medical Center and Misty Votaw. Topics they discussed included: Who should have their Lp(a) measured and when. Misty’s story and how the Family Heart Foundation provided resources. If you have elevated Lp(a), what can you do to reduce your risk of heart disease and stroke. What the Family Heart Foundation is doing to address gaps in care for 60 million Americans at risk. For more information and to find out if you have elevated Lp(a), contact the Family Heart Foundation’s Care Navigation team at FindLpa.org. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

March 25, 2024 01:13 PM Eastern Daylight Time

Video
Article thumbnail News Release

ECO Animal Health focused on innovation and global expansion as it grows its pipeline

Eco Animal Health Group PLC

ECO Animal Health Group PLC CEO David Hallas joins Proactive's Stephen Gunnion with more on the global animal health company focused on pigs and poultry. Hallas explained the company offers a variety of products aimed at maintaining animal health and treating diseases, particularly respiratory and intestinal issues. While a significant portion of its revenue is attributed to its flagship product, Aivlosin, he said the company maintains a diversified portfolio with operations in over 70 countries, more than 20 products, and around 200 licences for different indications. Hallas highlighted the company's fourth-quarter and full-year 2024 trading performance, driven by increasing demand for its products, especially Aivlosin, which assists in raising healthy animals to meet the global protein demand. The company's growth is notably robust in Brazil, a key protein producer. Hallas clarified that the company's operations and revenue are not overly dependent on China, with over 75% of revenue generated from outside this region. Despite challenges in the Chinese market reported by competitors, Hallas differentiates ECO Animal Health's sector from genetics, emphasizing its focus on animal health and prevention. The company is also expanding its product line with the upcoming launch of vaccine products in 2025, following recent trademark approvals in the EU, UK, and the US. Additionally, ECO Animal Health has initiated a limited share buyback, viewing it as an opportunistic use of funds following property disposals, while still prioritizing investments in innovation and the current business. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 21, 2024 12:26 PM Eastern Daylight Time

Video
Article thumbnail News Release

PainChek leads innovation in AI-based pain assessment

PainChek Ltd

PainChek Ltd (ASX:PCK), a medical device company, is pioneering the use of an app, leveraging artificial intelligence (AI) for pain assessment in vulnerable individuals unable to communicate their pain due to conditions such as dementia, cognitive impairments, or in pre-verbal children. In and interview with Proactive's Stephen Gunnion CEO and managing director Philip Daffas highlighted that PainChek's app is the world's first regulatory-cleared medical device for this purpose. It utilises AI for facial analysis to detect nine micro facial features indicative of pain, assisting carers in aged care and hospitals to document and score the severity of pain. PainChek has achieved a first mover advantage with patents in the US, Europe, Japan, and the UK, protecting its technology until 2038. The company has regulatory clearance in Australia, New Zealand, Canada, the UK, the EU, Singapore, and Malaysia, with ongoing clinical studies in the US aimed at FDA clearance. PainChek reported its fifth consecutive quarter of double-digit growth in the December quarter, with 85,000 licences across 1,400 aged care facilities on three continents. With an annual recurring revenue of around $4 million, the company sees a significant growth opportunity in aged care, home care, and the hospital sector. Key milestones for investors include expansion in regulatory-cleared markets, entry into the US market upon FDA clearance, and the launch of an infant app for pain assessment in the home. Contact Details Proactive Australia Pty Ltd Proactive Australia Pty Ltd +61 431 597 771 writers.australia@proactiveinvestors.com

March 21, 2024 12:07 PM Eastern Daylight Time

Video
Article thumbnail News Release

Ultrahuman Raises $35mn to accelerate growth and research in the health monitoring space

Ultrahuman

The pioneer in wearable tech Ultrahuman has today announced a $35 million equity and debt investment round. The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space. "This funding round marks a pivotal step forward in our journey to dominate the smart rings space, bringing us closer to our goal of being the market leader" remarked Mohit Kumar, co-founder of Ultrahuman. Ultrahuman is at the forefront of the health-tech revolution, boasting the world's largest and only multi-device health ecosystem. In addition to their smart ring called Ring Air, the Ultrahuman product suite includes a continuous glucose monitoring wearable called M1 Live, a home health device called Ultrahuman Home and a preventive blood testing product called Blood Vision. Their platform integrates glucose, sleep, movement, blood markers, and HRV, offering a comprehensive approach to health monitoring. "The future of health is integrated, and at Ultrahuman, we're making that future a reality today by seamlessly combining various health data streams to empower preventative health and wellness," said Mohit Kumar. Ultrahuman has seen phenomenal growth over the past 12 months, becoming the second-largest player in the smart ring market while maintaining profitability. "Our vision of being the top player in terms of both active devices and geographic presence is within reach, thanks to our rapid expansion and the love we've received from our users," added Mohit Kumar. A key driver of Ultrahuman's explosive growth has been its expansion into over 150 retail outlets worldwide, including iconic locations like London’s Selfridges on Oxford Street, Changi airport in Singapore, and the Virgin megastore in Dubai. This retail footprint expansion has been instrumental in introducing Ultrahuman's cutting-edge technology to a global audience. "Our growth is a testament to the user love for our products, highlighted by industry-leading NPS and engagement metrics since the launch of our latest model, the Ring Air. Our relentless focus on improving user experience through continuous firmware and software updates is what sets us apart," Mohit Kumar emphasized. "Shipping a new firmware version every 2 weeks and weekly app improvements reflect our commitment to excellence and our speed of execution, our biggest competitive advantage. We’ve also iterated in hardware at the speed of software by designing novel devices like Ultrahuman Home, a home health monitor.” Looking ahead, Ultrahuman is on track to surpass $100 million in annualized revenue run rate (ARR) by the end of 2024, a milestone that will be achieved profitably. "Our ability to make long-term manufacturing investments, supported by our profitability, is unique in the smart rings market," Mohit Kumar noted. UltraFactory, a recent addition of a new manufacturing facility, is capable of supporting $200 million in annual revenue, a clear indication of Ultrahuman’s readiness for its next phase of growth. Ultrahuman's dedication to scientific validation and innovation is further evidenced by the completion of a clinical trial involving 105 participants, aimed at validating the ‘Metabolic Score’ generated on the Ultrahuman platform. "Our long-term investment in R&D and intellectual property is a cornerstone of our strategy, ensuring that our products not only meet but exceed the highest standards of efficacy and reliability," Mohit Kumar concluded. About Ultrahuman Ultrahuman is the world's most advanced metabolic fitness platform. Ultrahuman’s products include the Ultrahuman M1(continuous glucose monitoring sensor), the Ultrahuman Ring and Blood Vision, a preventive blood testing platform with the pioneering UltraTrace™ technology. By collating different biomarkers, Ultrahuman is helping people improve their energy levels and lifestyle, track their workout, sleep and recovery, and avoid metabolic disorders. For more information and updates on Ultrahuman, please visit ultrahuman.com or follow us on Facebook, Instagram, Twitter, LinkedIn, and YouTube. Ultrahuman was started by Mohit Kumar and Vatsal Singhal, who were also co-founders at Runnr, which later merged with India’s largest food delivery service Zomato. Mohit is an avid cyclist and a Brazilian Jiu-Jitsu enthusiast. Vatsal is a cross-fit enthusiast. Mohit was training at one of the largest MMA Camps in the world (Tiger Muay Thai in Thailand). During his training, he observed athletes train smartly via the usage of data, recovery tools and protocols. About Nexus Venture Partners Nexus Venture Partners is a prominent venture capital firm specializing in early-stage investments. They focus on technology-driven startups across various sectors. With a successful track record, Nexus has supported numerous innovative companies in their growth journey. About Blume Ventures Blume Ventures is an India-based venture capital firm known for its strategic investments in early-stage startups. Their portfolio spans diverse domains, including technology, healthcare, and consumer products. Blume’s hands-on approach and mentorship have contributed to the success of several emerging companies. About Steadview Capital Steadview Capital is an investment firm that primarily targets late-stage and growth-stage companies. Their global portfolio includes disruptive startups across industries. Steadview’s investment philosophy emphasizes long-term value creation and sustainable growth. About Deepinder Goyal Deepinder Goyal is the Founder and CEO of Zomato, a leading food delivery and restaurant discovery platform. Under his leadership, Zomato has expanded globally, revolutionizing the way people explore and enjoy dining experiences. His entrepreneurial spirit and commitment to innovation continue to drive Zomato’s success. Contact Details Ultrahuman Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.ultrahuman.com/

March 20, 2024 08:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

American Aires Inc. (CSE:WIFI; OTC Pink:AAIRF) Proprietary Solution Against EMF Radiation Could Unlock Significant Shareholder Value

AAIRF, EDR, TKO

As the world gets more technologically advanced, there has been a dramatic rise in the number of electronic devices emitting electromagnetic fields (EMFs). EMFs are invisible energy areas associated with electrical power use, and while these EMFs have helped make our lives more convenient and connected, they have also had some unintended consequences. A number of scientific studies have shown that exposure to EMF radiation can trigger inflammation in the brain, which can lead to tissue damage and contribute to the development of various diseases, including neurodegenerative diseases. The results further demonstrated that there was a significant correlation between brain electrical activity and cognitive function, particularly in the areas of attention and working memory. Basically, using devices like your cell phone for just 30 minutes a day can increase brain tumor risks by 40%, while 24 hours of EMF exposure can induce more DNA damage than 1,600 chest x-rays. That is exactly why the Canadian-based nanotechnology company American Aires Inc. (CSE:WIFI) (OTC Pink:AAIRF), which is focused on enhancing well-being and environmental safety, has come up with what is possibly the perfect solution to this problem. American Aires has developed a proprietary silicon-based resonator that protects against the harmful effects of electromagnetic radiation. According to the company, its main goal was to find a way to minimize harm to the body without impacting the capability of electronic devices, which meant that the obvious solution was to modulate, rather than block or absorb radiation, to create a surrounding area free from the harm of EMF. So far, the company has dedicated over 20 years and poured at least $20 million into developing its proprietary nanotechnology, which has resulted in sleek and stylish, convenient devices that can be used for both personal and area protection without any need for a power source. Aires' Lifetune products target EMR emitted by consumer electronic devices such as cellphones, computers, baby monitors, and Wi-Fi, including the more powerful and rapidly expanding high-speed 5G networks. More importantly, the effectiveness of the American Aires Inc. (CSE:WIFI) (OTC Pink:AAIRF) microchip in reducing the harmful effects of EMF radiation has been reaffirmed by the scientific community. A recently published study in the Link Journal confirmed the chip’s stabilizing capabilities, while at least eight peer-reviewed studies and 25 clinical and scientific reports also validated the technology. Backed by such an impressive body of scientific research that supports the company’s technology, it’s no surprise that the company has been growing its topline at a healthy clip. Revenue growth has been robust, and over the past two years alone, the company has doubled its revenue consistently. According to the company’s most recent earnings results, Aires brought in $5.5 million in revenue for the first 9 months of 2022, representing a 63% YoY increase. Extrapolating this growth rate over the whole of 2023, Airestech could be sitting on $10 million in 2023 sales. What's even more appealing about American Aires Inc. (CSE:WIFI) (OTC Pink:AAIRF) is that it boasts superior profit margins. At the moment, its gross margins average about 60%, illustrating just how lucrative the opportunity in this space is. This level of profitability essentially puts Aires right up there with the top technology companies like Nvidia and Apple, which had 75% and 45% gross margins, respectively. The company also reached a key milestone after achieving positive EBITDA (adjusted) in its most recent quarter. A multi-billion-dollar market As you have probably realized by now, it is practically impossible to avoid EMF radiation in our technology-reliant world. That is why investors are taking a close look at American Aires Inc., which seems well positioned to capitalize on this huge opportunity. The market for Aires products is applicable to diverse customer segments, including biohackers, tech-savvy athletes, individuals focused on fertility, those seeking better sleep, and most recently, gamers. The U.S. market alone could be potentially worth $5 billion, which is just a tiny fraction of the global opportunity. Currently, American Aires Inc. (CSE:WIFI) (OTC Pink:AAIRF) operates an online direct-to-consumer sales model with fulfillment centers in the USA, Canada, Australia, and the EU and a customer base of 54,000 clients spread out across 65 countries. However, the company believes that it has the opportunity to further expand its reach now that its products have been especially popular among high-performing athletes and celebrities who value health and wellness. That explains why earlier this month Aires announced the launch of its new campaign, #airesathletes, to broaden its impact within the elite performance sphere, with UFC star Maycee Barber as the first athlete partner. Maycee "The Future" Barber is a formidable presence in the women's flyweight division of the Ultimate Fighting Championship (UFC). Last year, the UFC and WWE merged to form TKO Group (NYSE:TKO), and Aires’ initiative aims to connect with professional athletes who have turned to the company for the significant benefits its technology offers, particularly in terms of physiological optimization through EMF modulation as well as the proven protection from external EMF sources. And just earlier this week, American Aires Inc. (CSE:WIFI) (OTC Pink:AAIRF) announced that it had signed another strategic partnership with William Morris Endeavor Entertainment (WME), a titan in entertainment, sports, and fashion. WME is a leader in the global entertainment arena, bringing to the table a vast network of world-class artists, athletes, and content creators and a proven track record in talent management and strategic marketing. That means WME is perfectly positioned to elevate Aires' footprint, increasing brand reach and engagement and underscoring the extensive benefits of Aires' solutions for wellness and performance optimization. WME is part of Endeavor Group Holdings, Inc. (NYSE:EDR), a global sports and entertainment behemoth that has a 51% stake in TKO. This collaboration will harness the growing interest from elite athletes and performers in Aires' innovative solutions and capitalize on the momentum Aires has built among top-tier athletes, expanding on the recently launched #airesathlete campaign. Additionally, this partnership between American Aires and WME underscores a transformative vision: Aires Technology, already trusted by elite athletes and performers for its unmatched performance and recovery benefits, is poised to become a global standard for EMF protection and physiological optimization. CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by a third party to assist in the production and distribution of content related to American Aires Inc.. 'CGR' is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details CapitalGainsReport Mark McKelvie +1 585-301-7700 Markrmckelvie@gmail.com Company Website http://CapitalGainsReport.com

March 20, 2024 05:00 AM Eastern Daylight Time

Article thumbnail News Release

DREW BREES AND COPPER COMPRESSION TOUCHDOWN AT WALGREENS, REVOLUTIONIZING RECOVERY FROM ONLINE INTO AISLE

Copper Compression, LLC

In an exciting play for the recovery game, Copper Compression, the leading online health and wellness compression wear brand endorsed by football legend Drew Brees, announces today its expansion into over 1500 select Walgreens stores nationwide. This strategic partnership not only enhances Copper Compression’s accessibility, but also delivers new winning solutions for Walgreens’ health conscious consumers seeking premium wellness products not typically found at retail locations. “Partnering with one of the largest chain drug stores marks a significant milestone for Copper Compression and underscores the evolution of our brand,” says Super Bowl Champion, Drew Brees. “I’ve personally experienced faster recovery while using Copper Compression. Having these products available at Walgreens will be life-changing for people dealing with pain and in need of effective all-natural relief.” Walgreens will now carry a selection of six Copper Compression products featuring Brees including, the Recovery Shoulder Brace (an Amazon Best Seller), Calf Sleeves, a universal Finger Splint which features medical grade aluminum and the introduction of Coppervibe™, the latest innovation in wearable tech that combines Vibration and Heat for hands, back and knee relief. Copper Compression continues to garner recognition by millions of online fans for its lab-tested nylon compression all which is infused with the maximum copper advantage. Its full collection of products are also FDA approved and certified antimicrobial by the EPA; these standards lead to explosive growth, rave reviews and a loyal customer base which include celebrities Anna Wintour, DJ Khaled, Kid Rock and Kaley Cuoco. “The trend from online to inline continues to reflect a dynamic transformation in the retail landscape," adds Vincent Porpiglia, President of Hero Brands, “Fan favorite digital brands continue to emerge and prove themselves alongside legacy brands at brick-and-mortar. Copper Compression stands at the forefront of this movement, delivering its premium recovery solutions to your neighborhood Walgreens” About Copper Compression New York City-based Copper Compression is a health and wellness brand that designs, manufactures, and distributes the most diverse portfolio of cutting-edge copper-infused compression wearables tailored for pain relief and performance recovery. The company’s 100 unisex products include groundbreaking solutions for arthritis, tendonitis, and plantar fasciitis. Established in 2015, Copper Compression has served over 10 million satisfied customers and has been featured in Forbes, ESPN, Women’s World, US Weekly, and Sports Illustrated for its renowned commitment to effective, all-natural pain relief. Having amassed over 300,000+ authentic customer reviews from their online-first business model, Copper Compression swiftly expanded its success to over 10,000 national retail locations in less than 3 years, partnering with industry giants like Walmart, Walgreens, Publix, Ingles, and Harris Teeter. Copper Compression earned seven best seller badges on Amazon.com for its top-rated Half-Finger Arthritis Gloves and Arch Supports. Follow @CopperCompression on Instagram, TikTok and Facebook. Note to Editors: Photos available Here. Press Contacts: Nathan Lindsey NLindsey@adjmi.com 203.376.8154 Sarah Leheny SLeheny@adjmi.com 631.834.2815 Contact Details Copper Compression Joey Braha JBraha@adjmi.com Copper Compression Nathan Lindsey +1 203-376-8154 nlindsey@adjmi.com Copper Compression Sarah Leheny +1 631-834-2815 Company Website https://www.coppercompression.com/

March 19, 2024 08:30 AM Eastern Daylight Time

Video Image
Article thumbnail News Release

AGBOOST SCALES AI-ENABLED GENETIC DATA ANALYSIS SOFTWARE FOR CATTLE PRODUCERS

AgBoost

After years of product development and field testing, AgBoost announced the global commercial expansion of its cloud-based data analysis platform that helps cattle producers interpret genomic data for selective breeding, health, market value and nutrition management. Despite a 65% increase in U.S. beef herd productivity over five decades, according to United Stated Department of Agriculture (USDA), rising demand for sustainably produced meat and shrinking profit margins underscore the importance of genetic data for herd efficiency. "Too often, cattle producers invest in DNA technology without unlocking its full potential," said Sean Akadiri, founder and CEO of AgBoost, at the 2024 Animal AgTech Innovation Summit and World Agri-Tech Innovation Summit. "Our platform revolutionizes decision-making, empowering ranchers with faster, more precise choices. By putting genetics at their fingertips, we're reducing the average $2,000 loss per calf during breeding and development, giving ranchers a decisive advantage over the competition.” Traditionally, breeding decisions rely on visual appraisals and multi-generation written records of estimated genetic merit. AgBoost's software combines genomic and production data, including live birth weight and diverse phenotypic information, for individual animals. Users can track animals individually or group them, such as in replacement heifer groups. By selecting specific traits, producers gain a comprehensive view to inform feeding, animal health, and marketing decisions effectively. “Genomic testing data can feel like deciphering hieroglyphics to most producers. But AgBoost transforms complexity into simplicity, presenting data in a visual wheel that sparks meaningful conversations. Now, we can swiftly identify the top bulls with complementary traits for desired calves,” said Nick Jorgensen, CEO and CFO of Jorgensen Land and Cattle, who not only licenses the platform for its large seed stock operation but also invested in the company. Seedstock cattle producers depend on analytics for marketing in bull and production sales. AgBoost visually showcases genetic value and identifies DNA-linked traits, like production, maternal, and carcass traits, aiding in sorting and selecting specific characteristics. The tool also allows for scenario planning, including establishing keep/cull lines to distinguish the top and bottom of the gene pool. Poised for Rapid Expansion into New Geographies and Livestock Introduced to U.S. cattle producers in 2018, AgBoost now holds millions of genomic data records for individual cows. With recent patent approvals, the company aims to expand into top-producing markets like Brazil, Canada, China, and the United Kingdom. The global beef market, valued at $526.50 billion in 2023, is projected to grow at a 4.2 percent CAGR by 2030. Currently, AgBoost supports all sizes of seedstock and commercial cow/calf producers, regardless of breed association, with an interactive pedigree and sire link, with a breeding suggestion calculator coming in late 2024. As pioneers in the market, the company intends to broaden individual producer subscriptions, enterprise licensing agreements, and tailor the platform for additional livestock and related industries to meet current demand. For more information, visit www.Ag-Boost.com. About AgBoost Established in 2013 by engineers and cattle producers as a subsidiary of the animal agtech leader, Agric-Bioformatics, Inc., AgBoost pioneers affordable, user-friendly genetic management tools for livestock producers worldwide. Our comprehensive software streamlines the entire process—from ordering tests to interpreting data for actionable insights and creating effective marketing tools. At AgBoost, our mission is clear: to prioritize producers by empowering them to own and comprehend their data, unlocking maximum growth potential for the future. To learn more or request a demo, visit www.Ag-Boost.com. Contact Details AgTech PR for AgBoost Jennifer Goldston jennifer@agtechpr.com

March 18, 2024 12:17 PM Central Daylight Time

Image
Article thumbnail News Release

Abingdon Health CEO discusses strong interim results, robust pipeline and growth strategy

Abingdon Health PLC

Abingdon Health PLC (AIM:ABDX) CEO and co-founder Chris Yates discusses the company's interim results and business operations in an interview with Proactive's Stephen Gunnion. Abingdon Health is a lateral flow, contract development, and manufacturing organisation (CDMO), supporting customers from product ideation to commercial success. It offers services including development, scale-up manufacturing, regulatory and analytical laboratory provision, and packaging. Yates said a 117% revenue increase to £2.4 million during the interim period was primarily driven by its CDMO division. This growth was attributed to increases in development, operational revenues, and the emergence of regulatory area revenues. Despite an inflationary environment, Abingdon Health managed to maintain stable operating costs, resulting in improved gross margins to over 50%. The company has a robust opportunity pipeline with 29 ongoing projects, emphasizing its fully integrated solution's appeal to customers. Yates also highlighted a good start to the second half of the year, with revenues expected to grow significantly while controlling costs to enhance operating profit performance. Contact Details Proactive UK Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com

March 18, 2024 07:10 AM Eastern Daylight Time

Video
1 ... 45678 ... 95